Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06517186 · ClinicalTrials.gov registry record
Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
A clinical trial of Heart Failure and Heart Failure With Preserved Ejection Fraction, sponsored by Northwestern University.
- Recruiting
- Registry status
- 180
- Enrollment target
- 6
- Study locations
NCT06517186: Recruiting study of Heart Failure and Heart Failure With Preserved Ejection Fraction, sponsored by Northwestern University.
NCT06517186 is a study of Heart Failure and Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 180 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06517186, a study of Heart Failure and Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- 180 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure.
Conditions Studied
Study Locations (6)
Illinois
- Northwestern University - Chicago
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Mass General Brigham - Boston
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Wake Forest University - Winston-Salem
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-11-08 |
| Est. Completion | 2026-06 |
What NCT06517186 shows while recruiting
NCT06517186 is an observational study that tracks outcomes without assigning an intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 0 interventions.
NCT06517186 lists 6 locations in 6 states (Illinois, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06517186 about?
NCT06517186 is a clinical study titled "Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction". The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treat...
What is the current status of trial NCT06517186?
This trial is currently recruiting. The enrollment target is 180 participants. The study started on 2024-11-08. Estimated completion is 2026-06.
What conditions does trial NCT06517186 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction.
Who is sponsoring clinical trial NCT06517186?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06517186 being conducted?
This trial has 6 study locations across Illinois, Maryland, Massachusetts, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06517186's enrollment target sits among peer trials
180 176th of 397 higher than 221 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI